Thank you for joining Guggenheim's 3rd Healthcare Innovation Conference. My name is Moritz. I am part of the therapeutics team, and it is my privilege today to host Ian Somaiya, CFO of NewAmsterdam Pharma, and Matt Philippe, Head of IR. Thank you so much for making time for us, Ian and Matt. To start with, perhaps let us get everybody on the same page.
Can you briefly summarize the status of your ongoing PREVAIL study and your plans for the upcoming interim analysis?
Yeah. No, happy to do that. Thanks again for inviting us and hosting us this morning. It was great to get in front of investors and share with everyone the NewAmsterdam story. October marked my three years at NewAmsterdam, and just in reflecting on my short time here, it is amazing to see the progress we have made as a company and how close we are to delivering on the promise of obi and obi/eze. In those three years, we have had a company that has transitioned from delivering phase II data to now having completed the phase III LDL studies, with our partner launching, partner Menarini, launching the drug in Europe, specifically Germany, by the end of this year. It is a commercial reality. The drug will be available to patients.
As it relates to the broader clinical program, and I think that is the essence of your question, by the end of next year, we would have completed the remaining cardiovascular studies for obicetrapib, and these include the RUBENS trial, which is a study specifically in patients with type 2 diabetes as well as those with metabolic syndrome, but no semblance of ASCVD. This is a population of interest because there are 20, 30 million individuals that fit that risk in terms of have elevated LDL, have not had a previous event, but would benefit from a therapy like ours. The other trial is obviously PREVAIL. We remain on schedule to trigger the interim analysis by the end of this year, and we expect to hear back from the DSMB at some point in the first quarter of next year. Really, it has been a long trial.
It's a trial that we're very excited about in terms of the execution of the study and the design elements, which we think will support a positive outcome. I know the investor community is very keen to see the results. You can imagine that we are even more. That would be the next trial to read out for us. Then after that is REMBRANDT, and REMBRANDT is an outcome study for the fixed-dose combination. It's an imaging trial, and there's really nothing more powerful than an image, an image of seeing your plaque stabilize or potentially seeing plaques clear. It's akin to a cancer patient being able to visualize in an MRI, a PET scan, that their tumors have shrunk.
That's a trial that's been conducted by others in this space that resonate with clinicians, that resonate with patients, and it's a trial that we think will have important read-through and carry over to the commercial setting once that data becomes available, and that would be likely towards the end of next year.
Mm-hmm. Before we get more into PREVAIL, which is obviously top of everyone's mind, you already touched on RUBENS, and that one's perhaps maybe flown under the radar a little bit comparatively.
Yeah.
But maybe just touch a little bit more on the commercial importance of that, especially as it sort of relates to the differentiation versus statins and the kind of diabetes impact that those drugs have.
Yes, it is an important reminder that our drug does more than simply reduce LDL. One of the benefits that we have seen of the class has been, and this is of the CETP class, a reduction in the rate of new-onset diabetes. We saw that with the programs that were evaluated by major pharma companies in the past. We clearly saw that in our one-year BROADWAY study, where we showed roughly a 15% reduction in the rate of new-onset diabetes. I cannot emphasize this enough. There is a population at risk that has diabetes, that has elevated LDL, and if those patients were put on high-intensity doses of statins, their risk of converting from pre-diabetes to diabetes increases upwards of 36%.
When you look at our BROADWAY study data, where majority of the patients were on high-intensity statin, for us to be able to offset that risk and reduce the rate of new-onset diabetes, it is a benefit and an aspect of our profile that we think will resonate with patients and clinicians, and provides an important point of differentiation versus the established class. That is the statins, the ezetimibe, as we look at the PCSK9s, where the benefit is really limited to just LDL.
Makes sense. Now moving on to PREVAIL, and perhaps very topically, we just had AHA this weekend.
Yeah.
One of the key readouts there was the HORIZON study, which overall was neutral. But if you actually dig into the supplements of the New England Journal of Medicine paper, one of the subgroups that are shown is in the patients with more than 100 mg per deciliter of LDL-C at baseline, which is perhaps the population that is most similar to PREVAIL. Those patients actually did see a hazard ratio of 0.83, although with error bars that did overlap one.
Sure.
Still, there appears to be some trend perhaps. Overall, what do you think the HORIZON data means for PREVAIL, and where do you see the impact of LDL lowering of obicetrapib?
Yeah. No, I think that is a good way to frame it. There was a silver lining in what otherwise was a very somber presentation. Since I did not attend the meeting, I decided to spend time with family celebrating Diwali. I know, Matt, you were there. Maybe you can speak to it in more detail.
Yeah, I mean, I think it was obviously a kind of a disappointment for the Lp(a) class. But I think if you looked at it, a lot of the concerns that we had were echoed by the presenters, by the discussants at AHA is, maybe they lowered LDL-C too much. Maybe too many patients came off drug. So, it continues to be the question, was pelacarsen the right drug to answer the question of Lp(a)? I think as those who attended saw, there really was nothing there across every subgroup they looked at, except for LDL-C, where they started showing a trend.
I think what was interesting is one of the discussants clearly laid out that if you look at Lp(a) versus LDL-C and then kind of highlight the risk associated with as both those climb, what you clearly saw is that as LDL-C goes down, you almost eliminate the Lp(a) risk. But as Lp(a) goes down, there is still risk left over, and obviously lowering both together showed the greatest benefit. So, I think that's interesting, and as you noted as well, as Lp(a) went up, the trend was for a better MACE benefit. And I think for us, that's encouraging as well. But I think we all want to take a step back and remember, at the end of the day, PREVAIL is just based on LDL-C.
I think we did clearly hear from physicians that Lp(a) is still a risk factor and still a risk factor that their patients want something for. You may be able to tell your patient, "Let's just focus on your LDL and not worry about your Lp(a)," but it's so ingrained that Lp(a) is a genetic risk factor that those patients seem to want therapy, and I think being able to offer them something, we'll see when the future studies come out, how they replicate it, are we able to gain more information? But I think there's still a lot of unanswered questions, that hopefully, the next group of Lp(a) drugs are able to address.
Yeah. This is a trend that we also observed coming out of BROADWAY and BROOKLYN. So, when we published the analysis of the MACE trends in JACC last year, those patients that had higher Lp(a) had higher baseline LDLs. Those are the patients that benefited the most on obi. And what we don't know today is whether Lp(a) has a threshold effect. Is there a magic number that you need Lp(a) to get below for a patient to realize benefit from that treatment? And those are some of the questions we'll get answered in the future, with some of the other programs that continue. But to Matt, emphasizing Matt's point, the community is not getting away from Lp(a). There was a focus, a heightened focus on continuing to monitor for Lp(a) and being aggressive with treatments.
The way these patients have been treated up until now has been to get the LDL to the lowest possible number. And what that means is a requirement, a need for branded therapies. And this is why we are launching not only obi, but the fixed-dose combination with ezetimibe, and those two product forms allow patients to get their LDL to the lowest possible value.
I think I would just add, in terms of overall message or takeaway from AHA, I think outside of Lp(a), to Ian's point, there was still a renewed focus on being more aggressive on patients' LDL-C and getting patients to goal. I think that's really continued from ACC last or this year, where the guidelines have changed. I think this aggressive therapy and treatment, I mean, if anything, it potentially was highlighted by HORIZON that you should be more aggressive with LDL-C, even for Lp(a) patients, I think is a continuing theme and trend that we're hearing at the medical meetings.
Yeah. I know you didn't ask about ZEUS, but I think it makes sense to spend at least a minute on ZEUS. The learning and the silver lining there was if you looked at patients that did not have heart failure, there was a clear trend towards benefit. The parallels here are having the benefit of John and Michael be involved in the space, and the early decision they made to exclude patients with heart failure, simply because those patients are too far along to benefit from an LDL-lowering therapy. It's not just about the difference between an LDL study design based on the premise of LDL, which has been validated over and over again, versus Lp(a), where this is the first time the question's being asked.
It's also looking at how do you ensure, how do you design a study to produce a successful outcome? That's another lesson that we need to keep in mind.
Absolutely. Let's talk a little bit about the upcoming PREVAIL interim analysis.
You guided through a p-threshold of 0.01 for MACE-4. You haven't guided to a particular threshold for MACE-3, but you do need to hit on both for the interim to be successful. Can you talk a little bit perhaps about that decision not to pinpoint the threshold for MACE-3 exactly, and where you see the likelihood of MACE-4 and/or MACE-3 hitting based on the sort of blended blinded data that you've seen to date?
Yeah.
I mean—
Why don't you go ahead? It's okay.
I would say, when we look at the data, whether we look across sort of the CTT analysis, the REVEAL study, our BROADWAY study, our blinded data, they all point that we're heading in a very meaningful direction. I think that really was the crux of introducing the interim. We wouldn't have introduced an interim if we didn't think there was a chance of being successful. We've given ourselves that chance. I think from the statements we've said, and I'll reiterate here, is basically, we are well-powered at the interim. If we show a BROADWAY-like effect in both MACE-3 and MACE-4,
to stop the study. I think that information there kind of tells you everything you need to know about where we could be, what our alpha is, how much we're spending. Trying to fine-tune what the exact number is doesn't really matter that much. At the end of the day, the only thing that's going to matter is, do we hit the stats at that interim? If we do, hopefully the DSMB makes the recommendation to stop the study. But I think overall, there's not much we could We could give you the exact numbers, and that wouldn't change anything. I think the point is, by providing exact numbers, it makes it seem like the stats are infallible.
There's always risk with statistics, and we want to make sure people understand that, because if we do get a continue decision, we want to help people understand, you can't read too much into a continue. There's a lot of reasons that the study could continue. We could hit MACE-3, miss MACE-4, hit MACE-4, miss MACE-3. What we've known is we've seen several studies miss the interim. Unfortunately, companies, investors, everyone kind of reads too much into that, and then all of a sudden they're surprised when the end of the study comes around and it's exactly what they were expecting. I think a lot of investors really remember SELECT, some may remember Amarin. This was a very similar trend, and we've seen it through multiple other studies. So, we don't want to make it seem like if you do this, you get this.
All we can say is that we are well-powered, and with the stats that we have generated, and we're optimistic based on the data we've seen.
You've talked a lot about the trends that you're seeing in the blended blinded data, and that you've observed a slowdown relative to what you would expect. Can you talk a little bit more about that analysis, what exactly you've done—
Sure.
—and what it means to have seen a slowdown and why that makes you comfortable?
Well, let's start with the comparison to BROADWAY. It's a good comparison because BROADWAY was designed to be a mini PREVAIL, right? Nearly identical patient population. The two trials were enrolling patients at the same time, conducted at the same sites. We used the same adjudication committee. So, if there was a trial that provided a close comparator to PREVAIL, it was BROADWAY, and it was by design. So, what do we see in BROADWAY, and how does that relate to PREVAIL? This is something we've shared with you. So, when you look at the one-year data, and you look at the MACE-4 curves, you look at the MACE-3 curves, you look at the individual components of it, they're nearly on top of each other, if not absolutely on top of each other. So, check the box, the intended effect.
We wanted BROADWAY to give us a roadmap to PREVAIL, and looks like it has. We have provided additional updates since then because BROADWAY was limited by time. It was a one-year study. As we look at what has happened since the one-year mark, out to two years, we have seen rates continue to decline. We can all come up with reasons why our rates could decline, and Matt, I would encourage you to go through some of those, but we do believe it is a drug effect. We believe it is a drug effect because the rates are well below what would be expected in this population when looking at contemporary studies. Again, it is not a single point. It is not a single data point. It is looking at all the individual components, and they are all going in the right direction.
But I think, Matt, you should speak to what other factors could implicate and why we do not think those apply here.
Yeah, I think there are a couple of ways we have looked at that statement of the lowering rates. One, we can look at, fortunately, we are in an enviable position, sometimes to a detriment, that we have so much information about LDL-C reductions, and there have been so many cardiovascular outcome studies done in this space that you can actually build very good models about what should placebo patients do in these populations. You can either look for it and say, "Let us compare sort of the rate of placebo decay," because placebo does decay over time in the outcome studies, particularly from year one to year two. It is more linear in the out years, and it is actually more stable in MACE-3 than MACE-4.
But overall, you can look at that and say, "How is our placebo rate behaving, or how is our blinded rate behaving relative to other studies' placebo rates?" If we see something that is below that placebo rate, then the question is, how is it there? For us, and I will go into the other two points. I mean, there are three things. It could be standard of care has improved, driving down placebo rates. It could be drop-ins are driving down placebo rates, or it could be effect size is driving down your blinded rate. For us, we can kind of exclude standard of care and GLP-1, and I will talk about that. But what we are seeing is our blinded line is trending below. Now, there is always a lot of You have to be very careful with looking at blinded data.
I'd say the best thing we have, though, is there's all those caveats to head-to-heads comparisons, and Ian highlighted it well. We have BROADWAY, and that's a good starting point from there. You can also look at it and say, "If we adjust all these factors, all these variables based on our risk profile, what would we predict our placebo curve could do?" If we do it both those ways, we see it's lower. The big concerns I know a lot of people have are standard of care and drop-in rates, particularly drugs like GLP-1s. I think drop-ins are easier to explain. Our drop-in rate is around 1% a year. That level of drop-in rate is almost inconsequential in your overall event rate.
You'd have to assume that all of your drop-ins happen in the first day, and they all go to placebo arm, and even still then, a 1% rate in a 10,000-patient study is less than one basis point of potential impact. We know GLP-1s from BROADWAY, from other studies, you're just as likely to get them in the active group as you are in the placebo group, because these studies are well-balanced for BMI and diabetic risk. You're not going to preferentially go to the placebo group. Drop-ins are not there, and we've actually seen from other studies, the drop-in rates haven't really probably impacted things as much as well, especially for studies like VESALIUS and other LDL-C studies.
I know ZEUS highlighted it a little bit there, but you have to remember, their SGLT2 drop-in rate was so high because 40%+ of their patients had heart failure, so they were really trying to treat the heart failure, and that's what was driving that a little bit. The other question is standard of care, and I think what's interesting about standard of care is it does look like event rates have gone down over time in terms of MACE, but that can almost be completely explained by your LDL-C baseline. Actually interesting, even HORIZON's baseline MACE rates on that above 100 group was in line with exactly what we would expect for that group.
It tells you, even though those companies were out there saying, "Standard of care is driving down event rates," well, it was driving down event rates as you were driving down LDL-C so much. I think we can see now, even more recent studies, VESALIUS is a great point as well. The recent studies, if you adjust for baseline LDL-C risk, MACE rates have been pretty consistent over time, and that actually goes with the anecdotal data. We know standard of care has not actually improved. We know mortality has been increasing for the last decade. PCI procedures are relatively the same. Standard of care hasn't changed. What explains your event rate is really based on your LDL-C.
Makes sense. While we are talking about sort of recent studies, one that has come up also in a lot of discussions that we have had is the ACCELERATE study. If you look at just the headline number of that study, placebo adjusted, you see a 37% decrease in LDL-C, you see a 19% change in ApoB, which maps pretty closely with what obicetrapib has shown, but it turns out the ACCELERATE study was stopped soon after two years, but it was neutral. So why do you not view the ACCELERATE study as a good analog for PREVAIL? What are the key differences that investors need to be aware of?
Yeah. I would obviously encourage Matt to contribute to this. The most important is just the method that was used to measure LDL. The direct method, which was used by Lilly in that study, did likely overstate the LDL reduction that was sort of the true effect of the drug, and that is why the industry has moved away from the direct method to beta quantification, which is what every other subsequent study has used and what we have used in our trial. I think that is first and foremost. The other is the one you highlighted, which is a study that was too short in duration. It stopped at the two-year mark, and it is a question that will remain unanswered.
Were the trial to be extended, were the trial to be allowed to run longer, and you look at REVEAL as a comparison, four- to six-year study, which ultimately showed a quite robust treatment effect, would evacetrapib or ACCELERATE been similarly successful? The other is, there is just not a lot of details that are available from that trial, so we do not know, and this is a great question for Lilly, not for us, and what else could have contributed ultimately to that trial's failure? This is why I give Novartis a lot of credit for being as forthcoming as they were at the podium and providing not only the detail at the AHA, but also publishing it so we can all learn from that experience.
Yeah, the only thing I would add is, it is not uncommon for studies to take longer than two years. IMPROVE-IT also took longer than two years to show separation. I think there is probably a combination of multiple factors. It is just unfortunate. There are certain things that we cannot exclude. We cannot exclude that there is some sort of molecular difference with evacetrapib and something that the molecule was doing, because we do not have that data. We have that data for anacetrapib. We have that data for ourselves. We cannot exclude that separation could have occurred later. We do not know what their true LDL-C reduction was. The disconnect between their LDL-C and their ApoB is pretty staggering. They said 37 with direct and the 18% or whatever with their ApoB.
Anacetrapib said they were 41% with their direct assay and around 18% with their ApoB, but their beta quantification number was actually closer to 17%, 18%. I think it shows you can be drastically off with that. But we just unfortunately don't know the answers because we don't have the data. I think we have a lot more data of our own, a lot more data from anacetrapib and REVEAL, but I think ultimately there could be one or many factors that contribute to that difference with anacetrapib, I mean, evacetrapib.
Makes sense. Now that we're either going to get an answer at the interim or at the final analysis, can you just remind us, in either of those two scenarios, what does the NDA submission timeline look like for you?
Sure. The strategy is, and this goes back to the reasons why the outcome studies were started at the same time as the LDL, it's rare to have a company be able to deliver, share results from the outcome study at the time of launch. That's an important opportunity that we wanted to fully leverage, because it does provide payer access. It drives payer access, and it drives ultimately adoption. As we think about the PREVAIL and the two timelines, the interim or the final, I think what's great is they happen in the same calendar year, and I think that sometimes it bears reminding. Either we'll know the DSMB decision, or we'll know the DSMB decision in 1 Q and the trial would stop, or we'll have a study that concludes by the end of next year.
In terms of the filing strategy, if the timelines are driven by a positive interim analysis, we'll obviously file for approval as soon as possible. 90% of the application in the U.S. is the same as the one in Europe, so you can imagine a lot of that work has already been done, and we would want to wait to hear from the DSMB confirming the trial completion and be able to follow through with the filing. In terms of if the trial were to continue to the interim, sorry, to the final, that's a conversation we need to have with the FDA, whether we are able to file in advance of the trial completing or we do it concurrent with the completion of the study.
Amazing. Well, thank you both so much for taking the time to speak to us today.
Yeah.
Looks like we're at time already.
All right. Thank you, Moritz.